SML1814

3,6-DMAD hydrochloride

≥98% (HPLC)

• Synonim(y): N9-(3-(Dimethylamino)propyl)-N3,N3,N6,N6-tetramethylacridine-3,6,9-triamine hydrochloride
• Wzór empiryczny (zapis Hilla): C₂₂H₃₂N₅ · xHCl
• Numer CAS: 2187367-10-6
• Masa cząsteczkowa: 366.52 (free base basis)
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: desiccated

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• storage condition: desiccated
• color: yellow to orange
• solubility: DMSO: 25 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: CN(C)CCCNC1=C2C(C=C(N(C)C)C=C2)=NC3=C1C=CC(N(C)C)=C3
• InChI: 1S/C22H31N5/c1-25(2)13-7-12-23-22-18-10-8-16(26(3)4)14-20(18)24-21-15-17(27(5)6)9-11-19(21)22/h8-11,14-15H,7,12-13H2,1-6H3,(H,23,24)
• InChI key: UIWOQSJSDYDIQJ-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

3,6-DMAD is an acridine derivative that selectively suppresses ER stress- (300 nM Thapsigargin) induced HT1080 cellular XBP1 mRNA splicing (Eff. conc. 500 nM), but not eIF2a phosphorylation, by directly inhibiting IRE1? RNase (endoribonuclease) activity and disrupting IRE1α oligomerization. 3,6-DMAD is shown to exhibit anti-multiple myeloma efficacy in cultures in vitro (%survival/[3,6-DMAD]/cell line/24 h = 13%/4 M/RPMI 8226 and 8%/1 μM/MM1.R) and completely suppress the expansion of established RPMI 8226 tumor in mice in vivo when administered via intraperitoneal injection (10 mg/kg q.o.d.).

3,6-DMAD is an acridine derivative.

3,6-DMAD is also called as N⁹-(3-(dimethylamino)propyl)-N³,N³,N⁶,N6-tetramethylacridine-3,6,9-triamine. It prevents the development of multiple myeloma (MM) tumor xenografts.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable